Shall We Consider DPP-4-Inhibitors as Cardiovascular Safe Drugs?Jose Mario F de Oliveira*
Department of Medicine, Universidade Federal Fluminense, Brazil
- *Corresponding Author:
- Jose Mario F de Oliveira
Department of Medicine
Universidade Federal Fluminense, Brazil
E-mail: [email protected]
Received date: August 08, 2016; Accepted date: August 26, 2016; Published date: August 28, 2016
Citation: de Oliveira JMF (2016) Shall We Consider DPP-4-Inhibitors as Cardiovascular Safe Drugs? Diabetes Case Rep 1:111.
Copyright: © 2016 de Oliveira JMF. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cardiovascular diseases are by far the most frequent and deadly complications of type 2 diabetes mellitus. All recent anti-diabetic drugs have been shadowed by signals of more or less severe toxic side-effects, but the DPP-4 Inhibitors (DPP-4) have been gaining the reputation, based on interpretations of short and medium-term randomized clinical trials (RCT), and to pre-marketing rules of regulatory agencies, of being as a whole safe anti-diabetic drugs for type 2 diabetics.